EBMT 2023 | Indications for stem cell transplantation for patients with AML

Norbert-Claude Gorin, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses which patients with acute myeloid leukemia (AML) should proceed to autologous or allogeneic stem cell transplantation. Prof. Gorin explains that all patients with adverse risk AML according to ELN risk stratification should undergo stem cell transplantation. In addition, patients in the intermediate risk category should be considered for autologous transplantation if they do not carry the FLT3-ITD mutation. Finally, according to Prof. Gorin, patients with favorable risk AML should also be considered for autologous transplantation except if they carry the t(8;21) translocation or have M3 AML. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.